Immunization status of thirty patients with Sickle Cell disease five years post Hepatitis B vaccination: a comparison with normal controls
Artigo
em Inglês
| MedCarib
| ID: med-167
Biblioteca responsável:
JM3.1
Localização: JM3.1; R18.W4
ABSTRACT
In order for hepatitis B immunization programmes to be cost effective and clinically beneficial, vaccinated persons should maintain an immunity threshold titre of antibodies to hepatitis B surface antigen greater than 10 IU/L. Those who fall below this level should be boosted in order to be covered against the risk for which the vaccine was administered. Persons with sickle cell disease are included in the group for whom hepatitis B immunization is routinely prescribed. Antibody to hepatitis B surface antigen was measured in paired sera of thirty patients with sickle cell disease compared with a control group of healthy medical staff, five years post vaccination. There was no significant difference between patients with sickle cell disease and normal controls in the levels of antibody maintained or numbers that required booster vaccination. Recommendations for the maintanance of protection via revaccination should be the same for persons with sickle cell disease as for healthy persons. (AU)
Buscar no Google
Coleções:
Bases de dados internacionais
Contexto em Saúde:
ODS3 - Saúde e Bem-Estar
/
ODS3 - Meta 3.3 Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis
Problema de saúde:
Meta 3.3: Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis
/
Hepatite
Base de dados:
MedCarib
Assunto principal:
Imunização Secundária
/
Vacinas contra Hepatite B
/
Hepatite B
/
Anemia Falciforme
Tipo de estudo:
Guia de prática clínica
/
Estudo observacional
/
Fatores de risco
Limite:
Adolescente
/
Adulto
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Tipo de documento:
Artigo